STRATA Skin Sciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $589
- Price
- $0.0001
- % Change (Daily % change from the live per-ticker quote feed.)
- -50.00%
- Volume
- 860
About
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment. With a substantial global footprint, STRATA Skin Sciences distributes its solutions across the United States, Europe, the Middle East, Asia, Australia, South Africa, and both Central and South America. Its notable product portfolio includes the XTRAC and Pharos excimer laser systems, VTRAC lamp systems, and TheraClear treatment solutions. These technologies are instrumental in addressing common skin ailments such as psoriasis, vitiligo, and acne, among others. Domestically, the company engages directly with physicians for product distribution, while leveraging a network of international distributors to reach markets beyond the U.S. Established in 1989 and headquartered in Horsham, Pennsylvania, the company adopted its current name, STRATA Skin Sciences, Inc., in January 2016, having previously operated as MELA Sciences, Inc.
Quick stats
Shares outstanding5.9M
Computed float3.2M
Float / shares53.6%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001051514
AI Summary
AI-generated1/3
standardbullishexecutive change
STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
STRATA Skin Sciences appointed industry veteran Erica Jordan as Chief Executive Officer, effective July 12, 2026, succeeding Dr. Dolev Rafaeli. Jordan brings extensive experience from Revance Therapeutics and Envista Holdings, where she led commercial operations and strategy.
The new CEO's primary mandate is to scale the commercial organization and translate expanded CPT Code coverage into revenue growth. Chairperson Dr. Uri Geiger highlighted Jordan's proven track record in expanding sales operations in large markets.
STRATA focuses on dermatological conditions with products like the XTRAC excimer laser and TheraClearX Acne Therapy System. The company utilizes a partnership model to offer treatments on a fee-per-service basis, removing capital barriers for practices.